By Modupe Gbadeyanka
Thursday, March 8, 2018, has been fixed by the board of directors of GlaxoSmithKline Consumer Nigeria Plc for a crucial meeting to make decisions beneficial to both the company and shareholders.
At the gathering, the board will deliberate on the payment of dividend as well as the firm’s 2017 audited financial statements.
As a result, the company has announced the commencement of its closed period for dealing in its securities by the Directors, Managers or connected persons.
The closed period kicked off on Wednesday, February 21, 2018 and will terminate 24 hours after release of the result to the Nigerian Stock Exchange (NSE).
Business Post reports that during the March 8 board meeting, members will consider and approve the 2017 Audited Financial Statements, the amount to be recommended to members as dividend at the next Annual General Meeting (AGM), and fix the date and venue of the AGM.
more recommended stories
How T-Bills Rates Are Determined—DMO
By Dipo Olowookere The Debt Management.
NSE Lifts Suspension on RT Briscoe Shares
By Dipo Olowookere The restriction placed.
NNPC Supplies 1.6bn Litres of Petrol in 30 Days
**As Trade Surplus up by 46%.
Rapid Transformation of Wapic Insurance Excites Adekoya
By Dipo Olowookere Managing Director of.